Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Change in Receivables (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Change in Receivables for 2 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 7.91% to $1.7 million in Q4 2025 year-over-year; TTM through Oct 2025 was $7.8 million, a N/A change, with the full-year FY2025 number at $8.8 million, up 251.36% from a year prior.
  • Change in Receivables was $1.7 million for Q4 2025 at Kestra Medical Technologies, down from $1.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.9 million in Q3 2024 to a low of $1.1 million in Q2 2024.